Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H.
Van Cutsem E, et al. Among authors: fillet g.
Eur J Cancer. 1999 Jan;35(1):54-9. doi: 10.1016/s0959-8049(98)00353-0.
Eur J Cancer. 1999.
PMID: 10211088
Free article.
Clinical Trial.